Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00939510 · ClinicalTrials.gov registry record · Phase 1
Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer
A Phase 1 study of Prostate Cancer, sponsored by Robert Dreicer MD.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
- 1
- Study location
NCT00939510: Completed Phase 1 study of Prostate Cancer, sponsored by Robert Dreicer MD.
NCT00939510 is a Phase 1 study of Prostate Cancer that has completed, run by Robert Dreicer MD. The registered enrollment target is 32 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00939510, a Phase 1 study of Prostate Cancer, has completed, sponsored by Robert Dreicer MD.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. GM-CSF may stimulate the immune system in different ways and stop tumor cells from growing. Giving lenalidomide together with GM-CSF may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of lenalidomide when given together with GM-CSF and to see how well it works in treating patients with prostate cancer.
Primary Outcome
Number of patients with a PSA Response defined as a PSA decline greater or equal to 50% compared with baseline value.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG lenalidomide
- BIOLOGICAL sargramostim
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2005-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 1 |
What the finished NCT00939510 record still lists
NCT00939510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 3 interventions - of which laboratory biomarker analysis is the first listed.
NCT00939510 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00939510 about?
NCT00939510 is a clinical study titled "Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer". RATIONALE: Lenalidomide may stop the growth of prostate cancer by blocking blood flow to the tumor. GM-CSF may stimulate the immune system in different ways and stop tumor cells from growing. Giving lenalidomide together with GM-CSF may kill more tumor cells. PURPOSE: This phase I/II trial is study...
What is the current status of trial NCT00939510?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2005-07. Estimated completion is 2012-12.
What conditions does trial NCT00939510 study?
This clinical trial studies the following conditions: Prostate Cancer.
What interventions are being tested in trial NCT00939510?
The interventions under investigation include: laboratory biomarker analysis (OTHER), lenalidomide (DRUG), sargramostim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00939510?
This trial is sponsored by Robert Dreicer MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00939510 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00939510's enrollment target sits among peer trials
32 566th of 735 higher than 159 of 735 other Prostate Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia